Truvestments Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Truvestments Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.14K	Hold	248	–	–	﹤0.01%	851
2025 Q4	$5.79K	Hold	248	–	–	﹤0.01%	783
2025 Q3	$4.89K	Hold	248	–	–	﹤0.01%	826
2025 Q2	$5.38K	Hold	248	–	–	﹤0.01%	726
2025 Q1	$6.01K	Hold	248	–	–	﹤0.01%	736
2024 Q4	$5.18K	Hold	248	–	–	﹤0.01%	696
2024 Q3	$4.93K	Buy	+248	New	+$4.6K	﹤0.01%	689
2024 Q2	–	Sell	-391	Closed	-$6.23K	–	322
2024 Q1	$6.23K	Hold	391	–	–	﹤0.01%	536
2023 Q4	$6.57K	Hold	391	–	–	﹤0.01%	561
2023 Q3	$4.57K	Hold	391	–	–	﹤0.01%	520
2023 Q2	$5.25K	Hold	391	–	–	﹤0.01%	519
2023 Q1	$6.48K	Buy	+391	New	+$6.45K	﹤0.01%	478

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Truvestments Capital's CPRX Position: Q1 2026 in Review

Truvestments Capital held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 248 shares worth $6.14K. The position accounts for ﹤0.01% of the portfolio, ranked #851.

Truvestments Capital first reported a position in CPRX in Q1 2023 and has held it in 12 quarters since. The position peaked at $6.57K in Q4 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Truvestments Capital held 248 shares of Catalyst Pharmaceutical worth $6.14K as of Q1 2026.
Truvestments Capital left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #851 holding.
Truvestments Capital first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 12 quarters since.
Truvestments Capital's Catalyst Pharmaceutical position peaked at $6.57K in Q4 2023.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.